New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
22:11 EDTTKPYYTakeda highlights data on VELCADE treatment for multiple myeloma
Millennium: The Takeda Oncology company with its parent company Takeda Pharmaceutical announced results from two studies evaluating the safety and efficacy of VELCADE-based therapy. The first study reported data from a meta-analysis of VELCADE retreatment in patients with relapsed and/or refractory, R/R, multiple myeloma, MM. The second study ,'GIMEMA', evaluated VELCADE in combination with thalidomide as maintenance therapy for patients with previously untreated MM. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting held December 8-11 in Atlanta, GA. “The GIMEMA study continues to affirm the known overall survival benefit of VELCADE-based therapy in patients with previously untreated multiple myeloma,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium.
News For TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
05:16 EDTTKPYYTeva enters partnership with Takeda Pharmaceutical
Subscribe for More Information
November 20, 2015
16:55 EDTTKPYYTakeda confirms FDA approval of Ninlaro
Takeda Pharmaceutical Company Limited announced that the FDA has approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
10:52 EDTTKPYYFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use